Back to results
US 7,829,558 B2Granted
Fused ring heterocycle kinase modulators
AssigneeSGX Pharmaceuticals, Inc.
InventorsWilliam D. Arnold, Andreas Gosberg, Zhe Li, Ruo W. Steensma, Mark E. Wilson
Life of this patent
Estimating the term…
Abstract
The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity.
Claims35
A method of inhibiting the activity of a protein kinase comprising contacting said protein kinase with a compound having the formula:
- wherein
- L1 and L2 are independently a bond, —S(O)n—, —O—, —NH—, unsubstituted C1-C5 alkylene, or unsubstituted 2 to 5 membered heteroalkylene, wherein n is an integer from 0 to 2, and
- R1 and R2 are independently substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted aryl;
- with the proviso that R1 is not substituted or unsubstituted pyrrolyl, and that L1 is not unsubstituted 2 to 5 membered heteroalkylene when R1 and R2 are both unsubstituted phenyl, and that L1 is not —S(O)2— when R2 is unsubstituted piperazinyl, and that R1 is not substituted or unsubstituted isoxazolyl when R2 is unsubstituted pyridinyl.
1 more element
A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a compound having the formula:
- wherein
- L1 and L2 are independently a bond, —S(O)n—, —O—, —NH—, unsubstituted C1-C5 alkylene, or unsubstituted 2 to 5 membered heteroalkylene, wherein n is an integer from 0 to 2, and
- R1 and R2 are independently substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted aryl;
- with the proviso that R1 is not substituted or unsubstituted pyrrolyl, and that L1 is not unsubstituted 2 to 5 membered heteroalkylene when R1 and R2 are both unsubstituted phenyl, and that L1 is not —S(O)2— when R2 is unsubstituted piperazinyl, and that R1 is not substituted or unsubstituted isoxazolyl when R2 is unsubstituted pyridinyl.
1 more element
Dependencies are inferred from the claim text.